The Comparative Study Of SOX And FOLFOX6 In Advanced Colorectal Cancer

Objectives To analyze the OS,PFS,efficacy evaluation,toxicity and side effects of SOX and FOLFOX6 in advanced colorectal cancer,and provide the basis for the selection of clinical treatment plan.Methods Of tangshan people’s hospital were retrospectively analyzed with the division between January 2013 and January 2017,a total of 94 patients with metastatic colorectal cancer,and comparing the whole group of patients can be divided into two groups:(1)+ for gonow oxaliplatin into group(hereinafter referred to as the SOX group,n = 41);(2)oxaliplatin + 5-fu + folic acid calcium(hereinafter referred to as FOLFOX6 group,n=53).The differences in OS,PFS,therapeutic efficacy and toxicity were compared,and further stratification analysis was conducted according to single factor analysis results to screen the benefit groups.Results(1)the follow-up period ended on March 31,2018,and the follow-up rate was 100%.The survival rate of SOX group 1 and 3 years was 90.7% and 61.6%,and the survival rate was 95.9% and 59.7% in FOLFOX6 group,with no significant difference(χ2=89.446,P=0.905).The unprogression-free survival rate in SOX group 1 and 3 years was 67.6% and 38.8%,and the survival rate was 79.7% and 56.8% in group 1 and 3 years in FOLFOX6 group,and there was no significant difference between them(χ2=2.671,P=0.102).Further analysis showed that there was no progression survival rate in the FOLFOX6 group in patients with pretreatment distant organs metastasis and those receiving adequate cycles of chemotherapy,and the difference was significant(χ2=4.428、5.432,P=0.035、0.02).(2)efficacy analysis showed that there were 28 cases of SD in the SOX group,13 cases of PD and 68.3% of the total control rate.There were 43 cases of SD in FOLFOX6 group,10 cases of PD and 81.1% of total control rate.The total control rate of the two groups was not statistically significant(χ2=2.04,P=0.226).(3)the surgical stratification analysis results show that there are distant metastasis before treatment,the number of lymph node excision < 12 and in patients undergoing chemotherapy cycles enough application FOLFOX6 scheme chemotherapy can benefit in progression-free survival period(χ2=5.125、7.708、4.198,P=0.024、0.005、0.04).Distant metastasis group stratification analysis suggests that without vascular invasion,surgical treatment,T3 stage line,N2 stage,postoperative adjuvant radiotherapy,inpatients undergoing chemotherapy cycles enough application FOLFOX6 scheme chemotherapy can benefit in progression-free survival period(χ2 = 6.25 、 5.125 、4.148、5.511、7.046,P=0.039、0.024、0.042、0.019、0.008).(4)there were 10 cases(24.4%)of the white blood cells in the SOX group above the level of the above level,and the decrease of the white blood cells in the FOLFOX6 group was 11(21.2%),which was not statistically significant(P=0.566).SOX group Ⅱ magnitude neutrophils reduced 12 cases(29.3%),FOLFOX group Ⅱ magnitude neutrophils reduced to 10 cases(18.9%),the two comparison there was no significant difference(P=0.288);Above levels Ⅱ above reduced platelet and Ⅱ anemia on the comparison of differences between the two groups has no statistical significance(P=0.451、0.197).Conclusions(1)there was no significant difference in the treatment of metastatic colorectal cancer between SOX and FOLFOX6,and the incidence of the toxicity was similar.(2)stratified analysis showed that FOLFOX6 was used to benefit PFS in patients undergoing surgical treatment,late stage,distant metastasis,and patients receiving adequate cycles of chemotherapy.(3)the comparison between the SOX scheme and the FOLFOX6 scheme still requires a large scale clinical randomized controlled trial to explore further.